NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 96 filers reported holding NGM BIOPHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.75 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,886,004 | -58.7% | 6,435,518 | 0.0% | 0.23% | -43.1% |
| Q2 2023 | $16,667,992 | -36.5% | 6,435,518 | 0.0% | 0.41% | -51.8% |
| Q1 2023 | $26,256,913 | -18.7% | 6,435,518 | 0.0% | 0.85% | -13.9% |
| Q4 2022 | $32,306,300 | +356.4% | 6,435,518 | +1089.3% | 0.98% | +370.3% |
| Q3 2022 | $7,078,000 | +2.0% | 541,108 | 0.0% | 0.21% | -12.6% |
| Q2 2022 | $6,937,000 | -15.9% | 541,108 | 0.0% | 0.24% | -7.4% |
| Q1 2022 | $8,252,000 | +65.0% | 541,108 | +120.9% | 0.26% | +48.3% |
| Q3 2021 | $5,000,000 | +76.6% | 245,000 | +70.7% | 0.17% | +64.2% |
| Q2 2021 | $2,831,000 | -32.2% | 143,567 | 0.0% | 0.11% | -42.7% |
| Q1 2021 | $4,173,000 | -4.0% | 143,567 | 0.0% | 0.18% | -20.9% |
| Q4 2020 | $4,349,000 | -6.3% | 143,567 | -54.7% | 0.23% | -50.1% |
| Q2 2019 | $4,639,000 | – | 316,900 | – | 0.47% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RHO CAPITAL PARTNERS INC | 3,766,666 | $59,928,000 | 49.90% |
| Greenspring Associates, LLC | 1,573,357 | $25,032,000 | 38.95% |
| Svennilson Peter | 18,017,932 | $286,665,000 | 23.39% |
| Aquilo Capital Management, LLC | 1,018,334 | $16,202,000 | 1.72% |
| Jasper Ridge Partners, L.P. | 308,750 | $4,912,000 | 0.28% |
| Samsara BioCapital, LLC | 36,451 | $580,000 | 0.16% |
| Rock Springs Capital Management LP | 360,454 | $5,735,000 | 0.15% |
| Point72 Asset Management, L.P. | 1,611,850 | $25,645,000 | 0.13% |
| Virtus ETF Advisers LLC | 14,880 | $237,000 | 0.12% |
| WELD CAPITAL MANAGEMENT LLC | 15,238 | $242,000 | 0.10% |